Format

Send to

Choose Destination
J Heart Lung Transplant. 2014 May;33(5):486-91. doi: 10.1016/j.healun.2014.01.856. Epub 2014 Jan 24.

Results of the post-market Registry to Evaluate the HeartWare Left Ventricular Assist System (ReVOLVE).

Author information

1
Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; Clinic for Heart Surgery, Heart Center, Leipzig University, Leipzig, Germany. Electronic address: martin.strueber@med.uni-leipzig.de.
2
Advanced Heart Failure and Cardiac Transplant Service, Royal Perth Hospital, Perth, Western Australia, Australia.
3
Heart Lung Transplant Unit, St. Vincent׳s Hospital, Sydney, New South Wales, Australia.
4
Department of Cardiac Surgery, Medical University Vienna, Vienna, Austria.
5
Department for Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway.
6
Department of Transplantation, Papworth Hospital NHS Foundation Trust, Cambridge, UK.
7
Department of Cardiothoracic Transplantation & Mechanical Support, Royal Brompton & Harefield NHS Trust, Harefield Hospital, Harefield, London, UK.
8
Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.
9
HeartWare, Inc., Framingham, Massachusetts.
10
Department for Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, UK.

Abstract

BACKGROUND:

The post-market Registry to Evaluate the HeartWare Left Ventricular Assist System (ReVOLVE) is an investigator-initiated registry established to collect post-CE Mark Trial clinical data on patients receiving a HeartWare ventricular assist device (HVAD) in the European Union and Australia.

METHODS:

The ReVOLVE is a multi-center, prospective, single-arm registry performed at seven centers in Europe and two in Australia. Herein we describe a total of 254 commercial HVAD implants according to labeled indications between February 2009 and November 2012. Summary statistics included patients' demographics, adverse events, length of support and outcomes.

RESULTS:

Compared with the clinical trial supporting the CE Mark of the HeartWare system, patient selection differed in that patients were older, and there were higher proportions of females and patients with idiopathic cardiomyopathies in the ReVOLVE cohort. Duration of support ranged from 1 to 1,057 days, with a mean of 363 ± 280 days (median 299.5 days). Transplantation was done in 56 patients (22%), explant for recovery was performed in 3 patients (1%), 43 died while on support (17%), and 152 (60%) remain on the device. Success in patients with the HeartWare system was 87% at 6 months, 85% at 1 year, 79% at 2 years and 73% at 3 years. Adverse event rates were low, comparable or improved when compared to the CE Mark Trial.

CONCLUSION:

Real-world use of the HeartWare system continues to demonstrate excellent clinical outcomes in patients supported with the device.

KEYWORDS:

HVAD; HeartWare; ReVOLVE Registry; ventricular assist system

PMID:
24656285
DOI:
10.1016/j.healun.2014.01.856
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center